CVS Health Momentum: Analyst Sees Further Upside Amid Valuation Rerating

CVS Health (NYSE: CVS) has staged a significant recovery in 2026, with shares climbing over 25% year-to-date. This resurgence, fueled by positive developments in the Medicare sector, has prompted Wall Street analysts to adjust their outlooks. Notably, Mizuho analyst Ann Hynes recently raised her price target for the stock to $115, signaling confidence in the company’s ongoing operational momentum and its ability to consistently outperform market expectations.

Beyond the immediate price target, there is a growing argument that CVS Health may be undervalued relative to its peers in the diversified healthcare services industry. Currently trading at approximately 13.8 times forward earnings, the stock remains significantly cheaper than competitors like UnitedHealth Group, which commands a valuation in the low 20s. As the market increasingly recognizes CVS as a comprehensive healthcare services provider rather than a traditional pharmacy chain, a valuation rerating could be on the horizon.

If CVS Health continues to deliver double-digit earnings growth through 2027, the potential for share price appreciation extends well beyond the current $115 target. Should the market assign a higher forward earnings multiple to the company, some analysts suggest the stock could eventually reach levels near $150 per share. This shift in sentiment reflects a broader transition in how investors value integrated healthcare models, positioning CVS as a potential blue-chip leader for the remainder of the year.